Quanterix, a developer of molecular diagnostic tests, disclosed to regulators on Tuesday it has raised $2 million in convertible debt. Nine separate investors participated in the offering.

Quanterix is a development stage company innovating ultra-sensitive detection systems for use in research and in-vitro diagnostics. Quanterix Single Molecule Array (SiMoA) technology enables researchers and clinicians to gain completely new insights into disease by detecting previously hard to detect or undetectable biomarkers. For example, the unparalleled sensitivity of SiMoA allows the detection of very low virus concentrations at the earliest stages of infection without the need for amplification.

The digital nature of Quanterix's SiMoA technology results in a 1,000-fold improvement in sensitivity compared with current state-of-the art technology. This technology enables life science researchers to validate novel, low abundance biomolecules from In addition, healthcare practitioners can use SiMoA for improved diagnosis, therapy selection and disease monitoring.